174 related articles for article (PubMed ID: 22376076)
21. Intranasal erythropoietin ameliorates neurological function impairments and neural pathology in mice with chronic alcoholism by regulating autophagy‑related Nrf2 degradation.
Nie X; Wang W; Wang Q; Zhu D; Song H
Mol Med Rep; 2019 Feb; 19(2):1139-1149. PubMed ID: 30535439
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system.
Sirén AL; Fasshauer T; Bartels C; Ehrenreich H
Neurotherapeutics; 2009 Jan; 6(1):108-27. PubMed ID: 19110203
[TBL] [Abstract][Full Text] [Related]
23. Second-generation non-hematopoietic erythropoietin-derived peptide for neuroprotection.
Cho B; Yoo SJ; Kim SY; Lee CH; Lee YI; Lee SR; Moon C
Redox Biol; 2022 Feb; 49():102223. PubMed ID: 34953452
[TBL] [Abstract][Full Text] [Related]
24. Neuroprotection and endocytosis: erythropoietin receptors in insect nervous systems.
Miljus N; Massih B; Weis MA; Rison JV; Bonnas CB; Sillaber I; Ehrenreich H; Geurten BR; Heinrich R
J Neurochem; 2017 Apr; 141(1):63-74. PubMed ID: 28142212
[TBL] [Abstract][Full Text] [Related]
25. Development of a Neuroprotective Erythropoietin Modified with a Novel Carrier for the Blood-Brain Barrier.
Chiu PC; Liou HC; Ling TY; Shen LJ
Neurotherapeutics; 2020 Jul; 17(3):1184-1196. PubMed ID: 32144722
[TBL] [Abstract][Full Text] [Related]
26. Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis.
Savino C; Pedotti R; Baggi F; Ubiali F; Gallo B; Nava S; Bigini P; Barbera S; Fumagalli E; Mennini T; Vezzani A; Rizzi M; Coleman T; Cerami A; Brines M; Ghezzi P; Bianchi R
J Neuroimmunol; 2006 Mar; 172(1-2):27-37. PubMed ID: 16337691
[TBL] [Abstract][Full Text] [Related]
27. Intranasal delivery of erythropoietin plus insulin-like growth factor-I for acute neuroprotection in stroke. Laboratory investigation.
Fletcher L; Kohli S; Sprague SM; Scranton RA; Lipton SA; Parra A; Jimenez DF; Digicaylioglu M
J Neurosurg; 2009 Jul; 111(1):164-70. PubMed ID: 19284235
[TBL] [Abstract][Full Text] [Related]
28. Short-term intra-nasal erythropoietin administration with low sialic acid content is without toxicity or erythropoietic effects.
Lagarto A; Bueno V; Sanchez JA; Couret M; Valdes O; Barzaga P; Lopez R; Guerra I; Gabilondo T; Vega Y; Beausoleil I
Curr Neurovasc Res; 2012 Nov; 9(4):233-8. PubMed ID: 22962865
[TBL] [Abstract][Full Text] [Related]
29. A neuroprotective derivative of erythropoietin that is not erythropoietic.
Doggrell SA
Expert Opin Investig Drugs; 2004 Nov; 13(11):1517-9. PubMed ID: 15500399
[TBL] [Abstract][Full Text] [Related]
30. Neuroprotective role of erythropoietin in neonates.
Juul S
J Matern Fetal Neonatal Med; 2012 Oct; 25 Suppl 4():105-7. PubMed ID: 22958035
[TBL] [Abstract][Full Text] [Related]
31. Erythropoietin and Nrf2: key factors in the neuroprotection provided by apo-lactoferrin.
Zakharova ET; Sokolov AV; Pavlichenko NN; Kostevich VA; Abdurasulova IN; Chechushkov AV; Voynova IV; Elizarova AY; Kolmakov NN; Bass MG; Semak IV; Budevich AI; Kozhin PM; Zenkov NK; Klimenko VM; Kirik OV; Korzhevskii DE; Menshchikova EB; Vasilyev VB
Biometals; 2018 Jun; 31(3):425-443. PubMed ID: 29748743
[TBL] [Abstract][Full Text] [Related]
32. Intranasal erythropoietin therapy in nervous system disorders.
Genc S; Zadeoglulari Z; Oner MG; Genc K; Digicaylioglu M
Expert Opin Drug Deliv; 2011 Jan; 8(1):19-32. PubMed ID: 21143002
[TBL] [Abstract][Full Text] [Related]
33. Neuroprotection in stroke in the mouse with intravenous erythropoietin-Trojan horse fusion protein.
Fu A; Hui EK; Lu JZ; Boado RJ; Pardridge WM
Brain Res; 2011 Jan; 1369():203-7. PubMed ID: 21047502
[TBL] [Abstract][Full Text] [Related]
34. Derivatives of erythropoietin that are tissue protective but not erythropoietic.
Leist M; Ghezzi P; Grasso G; Bianchi R; Villa P; Fratelli M; Savino C; Bianchi M; Nielsen J; Gerwien J; Kallunki P; Larsen AK; Helboe L; Christensen S; Pedersen LO; Nielsen M; Torup L; Sager T; Sfacteria A; Erbayraktar S; Erbayraktar Z; Gokmen N; Yilmaz O; Cerami-Hand C; Xie QW; Coleman T; Cerami A; Brines M
Science; 2004 Jul; 305(5681):239-42. PubMed ID: 15247477
[TBL] [Abstract][Full Text] [Related]
35. Erythropoietin in stroke: quo vadis.
Digicaylioglu M
Expert Opin Biol Ther; 2010 Jun; 10(6):937-49. PubMed ID: 20394473
[TBL] [Abstract][Full Text] [Related]
36. High-dose erythropoietin alters platelet reactivity and bleeding time in rodents in contrast to the neuroprotective variant carbamyl-erythropoietin (CEPO).
Kirkeby A; Torup L; Bochsen L; Kjalke M; Abel K; Theilgaard-Monch K; Johansson PI; Bjørn SE; Gerwien J; Leist M
Thromb Haemost; 2008 Apr; 99(4):720-8. PubMed ID: 18392330
[TBL] [Abstract][Full Text] [Related]
37. Intranasal recombinant human erythropoietin protects rats against focal cerebral ischemia.
Yu YP; Xu QQ; Zhang Q; Zhang WP; Zhang LH; Wei EQ
Neurosci Lett; 2005 Oct; 387(1):5-10. PubMed ID: 16054296
[TBL] [Abstract][Full Text] [Related]
38. Recombinant human erythropoietin offers neuroprotection through inducing endogenous erythropoietin receptor and neuroglobin in a neonatal rat model of periventricular white matter damage.
Zhu L; Huang L; Wen Q; Wang T; Qiao L; Jiang L
Neurosci Lett; 2017 May; 650():12-17. PubMed ID: 28359933
[TBL] [Abstract][Full Text] [Related]
39. Erythropoietin improves long-term neurological outcome in acute ischemic stroke patients: a randomized, prospective, placebo-controlled clinical trial.
Tsai TH; Lu CH; Wallace CG; Chang WN; Chen SF; Huang CR; Tsai NW; Lan MY; Sung PH; Liu CF; Yip HK
Crit Care; 2015 Feb; 19(1):49. PubMed ID: 25888250
[TBL] [Abstract][Full Text] [Related]
40. Neuroprotective properties and mechanisms of erythropoietin in in vitro and in vivo experimental models for hypoxia/ischemia.
van der Kooij MA; Groenendaal F; Kavelaars A; Heijnen CJ; van Bel F
Brain Res Rev; 2008 Nov; 59(1):22-33. PubMed ID: 18514916
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
